{"id":"NCT05568615","sponsor":"Mitsubishi Tanabe Pharma Corporation","briefTitle":"Extension Study Following the Studies MT-1186-A03 or A04 to Evaluate the Safety of Oral Edaravone in Subjects With ALS","officialTitle":"Multicenter, Open-label Extension Study Following the Studies MT-1186-A03 or A04 to Evaluate the Safety of Oral Edaravone in Subjects With Amyotrophic Lateral Sclerosis (ALS)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2022-10-26","primaryCompletion":"2023-06-27","completion":"2023-06-27","firstPosted":"2022-10-05","resultsPosted":"2025-02-03","lastUpdate":"2025-02-03"},"enrollment":15,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["ALS"],"interventions":[{"type":"DRUG","name":"MT-1186","otherNames":["Edaravone"]}],"arms":[{"label":"MT-1186 orally","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the safety of oral edaravone at a dose of 105 mg administered once daily for 10 days out of a 14-day period, followed by a 14-day drug-free period. This study will be continued until the earlier date when oral edaravone is commercially available at each site in Japan or August 2023.","primaryOutcome":{"measure":"Number of Patients With AEs and Adverse Drug Reactions","timeFrame":"up to 8 months","effectByArm":[{"arm":"MT-1186","deltaMin":6,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":3},"locations":{"siteCount":11,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":15},"commonTop":["Otitis externa","Tinea cruris","Constipation","Eczema","Decubitus ulcer"]}}